Overview

TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase I, open-label, single sequence drug-drug interaction trial in human immunodeficiency virus-type 1 infected patients is to investigate the potential interaction between steady-state nevirapine (NVP) 200 mg b.i.d. (twice a day) and a single dose of 400 mg TMC207 and to explore the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body).

Phase:

Phase 1

Details

Lead Sponsor:

Tibotec BVBA

Treatments:

Bedaquiline
Diarylquinolines
Nevirapine